SAGE Therapeutics Inc.'s brexanolone could become a game-changing treatment for postpartum depression, but only if it is administered in a highly-controlled setting, US FDA advisory committee members said.
Members of the joint Psychopharmacologic Drugs and Drug Safety and Risk Management advisory committees gave an overwhelmingly positive recommendation of...